Cited by 209Adipokines, Inflammation, and Metabolic DiseasesNitric Oxide and Endothelin EffectsPancreatic function and diabetes

A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice

Open access
Fujimoto, Masaki, Shimizu, Nobuyuki, Kunii, Kaiko, Martyn, J.A. Jeevendra, Ueki, Kohjiro, Kaneki, Masao·2005·Diabetes

Abstract

Chronic inflammation has been postulated to play an important role in the pathogenesis of insulin resistance. Inducible nitric oxide synthase (iNOS) has been implicated in many human diseases associated with inflammation. iNOS deficiency was shown to prevent high-fat diet-induced insulin resistance in skeletal muscle but not in the liver. A role for iNOS in fasting hyperglycemia and hepatic insulin resistance, however, remains to be investigated in obesity-related diabetes. To address this issue, we examined the effects of a specific inhibitor for iNOS, L-NIL, in obese diabetic (ob/ob) mice. iNOS expression was increased in the liver of ob/ob mice compared with wild-type mice. Treatment with iNOS inhibitor reversed fasting hyperglycemia with concomitant amelioration of hyperinsulinemia and improved insulin sensitivity in ob/ob mice. iNOS inhibitor also increased the protein expression of insulin receptor substrate (IRS)-1 and -2 1.5- and 2-fold, respectively, and enhanced IRS-1- and IRS-2-mediated insulin signaling in the liver of ob/ob mice. Exposure to NO donor and ectopically expressed iNOS decreased the protein expression of IRS-1 and -2 in cultured hepatocytes. These results suggest that iNOS plays a role in fasting hyperglycemia and contributes to hepatic insulin resistance in ob/ob mice.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.54.5.1340

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Use of an NOS2-specific inhibitor (L-NIL) reverses hyperglycemia, hyperinsulinemia, and insulin resistance in ob/ob mice.

    “and the use of an NOS2-specific inhibitor (L-NIL) reversed hyperglycemia, hyperinsulinemia, and insulin resistance in ob/ob mice [150].”

    From Regulation of obesity and insulin resistance by nitric oxide (2014) · cites this paper as [150]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fujimoto, M., Shimizu, N., Kunii, K., Martyn, J. A. J., Ueki, K., & Kaneki, M.
Affiliations
  • Harvard University (US)
  • The University of Tokyo (JP)
Venue
Diabetes
Published
2005-05-01
Volume
54
Issue
5
Pages
1340-1348
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2138266804
Cited by
209
References
47
Citations by year
2026: 3 · 2025: 3 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 9 · 2019: 15 · 2018: 12 · 2017: 10 · 2016: 10 · 2015: 24 · 2014: 14 · 2013: 7 · 2012: 15
FWCI
4.32
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Shriners Hospitals for Children
  • National Institutes of Health
  • National Institute of General Medical Sciences (R01GM055082, R01GM031569, R01GM061411)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK058127)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
Keywords
inducible nitric oxide synthase, fasting hyperglycemia, hepatic insulin resistance, insulin signaling, IRS-1, insulin receptor substrate 2, L-NIL, ob/ob mice, obesity, type 2 diabetes, nitric oxide, chronic inflammation, hepatocytes
MeSH terms
Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Enzyme Inhibitors, Fasting, Hyperglycemia, Insulin, Insulin Resistance, Liver, Lysine, Male, Mice, Obese, Signal Transduction, Nitric Oxide Synthase, Phosphatidylinositol 3-Kinases, Nitric Oxide Donors, Hepatocytes, Mice, Nitric Oxide Synthase Type II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review